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Abstract: Sodium dichloroacetate (DCA) is an investigational medicinal product which has a potential
anticancer preparation as a metabolic regulator in cancer cells’ mitochondria. Inhibition of pyruvate
dehydrogenase kinases by DCA keeps the pyruvate dehydrogenase complex in the active form,
resulting in decreased lactic acid in the tumor microenvironment. This literature review displays the
preclinical research data on DCA’s effects on the cell pyruvate dehydrogenase deficiency, pyruvate
mitochondrial oxidative phosphorylation, reactive oxygen species generation, and the Na+–K+–2Cl−
cotransporter expression regulation in relation to gender. It presents DCA pharmacokinetics and
the hepatocarcinogenic effect, and the safety data covers the DCA monotherapy efficacy for various
human cancer xenografts in vivo in male and female animals. Preclinical cancer researchers report
the synergistic effects of DCA combined with different drugs on cancer by reversing resistance
to chemotherapy and promoting cell apoptosis. Researchers note that female and male animals
differ in the mechanisms of cancerogenesis but often ignore studying DCA’s effects in relation to
gender. Preclinical gender-related differences in DCA pharmacology, pharmacological mechanisms,
and the elucidation of treatment efficacy in gonad hormone dependency could be relevant for
individualized therapy approaches so that gender-related differences in treatment response and safety
can be proposed.
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1. Introduction
Sodium dichloroacetate (DCA) is an investigational medicinal product which has been employed
in experimental and clinical research. It has a potential anticancer preparation, derived from in vitro
and animal research, as a metabolic regulator in cancer cells, and it has been proposed to cause multiple
changes in cancer cells such as reversing the glycolytic cell phenotype [1–4].
The main known DCA pharmacological mechanisms are as follows: (1) the principal site of DCA
action is the mitochondrial pyruvate dehydrogenase complex (PDC), where inhibition of pyruvate
dehydrogenase kinases (PDK) keeps PDC in the unphosphorylated active form, facilitating the
oxidative removal of pyruvate and the mitochondrial oxidation of glucose. Sodium dichloroacetate
may help stabilize the PDC escaping pyruvate dehydrogenase deficiency and DCA treatment results in
decreased lactic acid generation in the tumor microenvironment [1,2,5,6]. (2) Sodium dichloroacetate
treatment is accompanied by an increase in reactive oxygen species (ROS) generation leading to a
number of pro-apoptotic changes in cancer cells [7]. (3) Sodium dichloroacetate works as Na+–K+–2Cl−
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cotransporter (NKCC) inhibitor, and such a pharmacological effect could be important in anticancer
efficacy [8]. (4) There are preclinical research reports on the synergistic effects of DCA combined with
different drugs or radiation therapy on cancer by reversing resistance to chemotherapy or radiation
and promoting cancer cell apoptosis, or by increasing or reducing the cytotoxicity of anticancer
agents [9–11].
Sodium dichloroacetate has been assigned for clinical research as it received the designation as
an orphan medicine for the continuous therapy of rare diseases such as congenital lactic acidosis,
malaria, homozygous familial hypercholesterolemia, conditions related to acquired lactic acidosis, and
pulmonary arterial hypertension as a hyperproliferative disease [12].
The results of a few small clinical trials suggest that the chronic administration of DCA is usually
well tolerated and might have effects against some human cancers. Doses up to 6.25 mg/kg of body
weight twice daily can be administered safely, but no controlled clinical trials of DCA in cancer patients
are available. Thus, the efficacy and safety of advanced or refractory solid tumors treated with DCA
can be neither supported nor negated and requires further study [13–15].
The regulatory guidelines for pharmaceutical studies require the evaluation of gender differences,
indicating that the medicinal product development process should provide adequate information
about the efficacy of medicines in both genders [16,17].
This literature review focused on the growing number of DCA preclinical studies in the cancer area
in vivo. Preclinical gender-related and gonad hormone-dependent DCA treatment efficacy elucidation
could be important for an individualized therapy approach so that gender-related differences in
treatment response and safety can be predicted.
2. Methods
A keyword search was conducted in the PubMed database: “dichloroacetate”, “cancer”,
“preclinical”, “male”, “female”, “PDK”, “PDC”, “ROS”, “NKCC1”, “pharmacokinetics”,
“hepatocancerogenesis”, “side effects”, and a combination of keywords of the study points. The
search included studies in vivo of any animal species and their experimental models. Sodium
dichloroacetate experimental monotherapy and its combination efficiency with authorized therapy
concerning human xenograft cancers in male and female animals were retrieved. The data on
sex-related mitochondrial function dimorphism, mitochondria-related genes expression, and DCA
metabolism-related factor differences in intact males and females were examined as factors that could
have an impact on gender-related DCA pharmacology and anticancer mechanisms. The article type
searched for was peer-reviewed publications and the language was English. The reference search was
repeated on newly identified items until no additional relevant article was found.
3. Gender-Related DCA Effect on Pyruvate Dehydrogenase Deficiency
Sodium dichloroacetate is a structural analog of pyruvate, which, by inhibiting PDK, stimulates
pyruvate dehydrogenase (PDH) activity. It inhibits all isoforms of PDK keeping the mitochondrial
PDC (made up of E1α, E1β, E2, and E3 PDH subunits) in the active form [18–20]. The E1α subunit
(PDHA1) gene is located on the X chromosome [21]. Such a gene location has different consequences
for males and females with PDHA1 deficiency and may cause gender-related clinical problems mainly
depending on the amount of residual PDH enzyme activity [22]. The PDC activity is tightly regulated
through phosphorylation of PDH1 by deactivated PDK and activated phosphatase, and changes in
PDC enzymatic activity which deactivates PDH1 renders the entire complex inactive [23]. The PDH
is present in all tissues, and its deficiency is a cause of primary or acquired lactic acidosis which
depends on the equilibration of pyruvate with lactate [24,25]. Sodium dichloroacetate treatment may
help stabilize PDC escaping PDH deficiency, which leads to differences in mitochondrial activity
from chronic DCA exposure. Sodium dichloroacetate reactivates PDC and consequently promotes
oxidative metabolism in the mitochondria: the metabolism of pyruvate shifts from glycolysis towards
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oxidative phosphorylation, lowering lactate production, and this has been exploited in lactic acidosis
treatment [4,25,26].
The PDK N-terminal domain contains a binding site for pyruvate and for its analog DCA; DCA,
pyruvate, nicotinamide adenine dinucleotide (NAD+), and acetyl-CoA (CoA), a two-carbon acetyl unit,
exert substrate activation of PDC by inhibiting PDK [1]. Repeated DCA dosing leads to a sustained
increase in the PDC activity [18,27].
The PDC activity was higher in young females than in corresponding male mice and decreased
after ovariectomy but not after orchidectomy, indicating that PDC activity depends on female steroids;
gender differences in brain mitochondrial respiration are suppressed with a decline in the level of
ovarian steroids in mice, and this supports the suggestion that female steroids have an impact on
glycolysis [28]. Others have reported that female gonad hormone deficiency decreases PDC activity in
mice [29]. Administration of 17β-estradiol to ovariectomized female rats increases the PDC subunits
expression and modifies PDC phosphorylation processes [30–32]. Adult male rats showed a higher
expression of PDC-associated genes compared to females [33].
4. Oxidative Phosphorylation of Pyruvate and Gender
Mitochondria play a major role in bioenergetics in mammalian cells. The PDH active state is
linked to the mitochondrial energy generation process through the tricarboxylic acid (TCA) cycle
generating acetyl-CoA and adenosine triphosphate (ATP). Female gonadal steroids can influence the
activity of some TCA cycle enzymes [34]. Compared with young males, higher pyruvate oxidation
rates in young female mice were observed, and a decline in ovarian steroid levels was concomitant
with decreased PDC activity, but this was not so in males after orchidectomy [28,29]. When cells are
affected by PDH deficiency, the amount of pyruvate accumulated and adenosine diphosphate (ADP)
generated is reduced: cells are dependent on carbohydrate aerobic oxidation. The PDK inhibition by
DCA consequently diverts more pyruvate into the TCA cycle [1,35]. Oxidative phosphorylation (of
pyruvate by the mitochondrial respiratory chain, which is composed of five complexes—complex I
through complex V (C I–C V)) is the major pathway of ATP synthesis [36]. The PDC catalyzes the step
generation of cofactors nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide
(FADH2): NADH-linked respiration depends on the activities of PDC, TCA cycle enzymes, C I, C III,
and C IV; FADH2-linked respiration depends on the activities of C II, C III, and C IV and the efficiency
of the phosphorylating apparatus generating ATP from ADP and inorganic phosphate [28,37–39].
Gonadal hormones modulate mitochondrial respiratory chain biogenesis [40,41]. Estrogen in
neurons enhances mitochondrial bioenergetics and sustains aerobic glycolysis and TCA cycle-driven
ATP production [42]. There are sex differences of mitochondrial function in brain cells: the NADH-linked
respiration rate was higher in young female than in matched male mice; it was higher in females when
the respiratory donor substrate pyruvate was used [28]. Others reported a decrease of C I+III, C II, and
C IV activities in mitochondria isolated from female mice cortices 28 days after ovariectomy [43] and a
decrease of the C IV activity in mice mitochondria isolated from the brain 90 days after ovariectomy [29].
A higher expression of proteins associated with C III–C V of oxidative phosphorylation and the rate of
mitochondrial oxygen consumption in the heart of old female monkeys as compared to age-matched
males was reported. [44]. Others noted that only complexes I and IV were significantly different
between the genders: they were higher in female as compared to male rats [33]. Sodium dichloroacetate
treatment increased the NAD+/NADH ratio, and this is consistent with the enhanced C I activity leading
to the increased oxidation of NADH generated during glycolysis and TCA cycle. There is an inverse
relationship between lactate/pyruvate and NAD+/NADH ratios [45,46]. Male murine aortas show
higher activity of C IV (cytochrome c oxidase) than in females, and orchiectomy abolishes the gender
difference, whereas testosterone administration induces an accretion of C IV RNA, protein, and its
elevated activity [47]. The higher expression of genes associated with oxidative phosphorylation in the
heart of old female rats as compared to males may suggest a greater oxidative potential of mitochondria
in females [33]. Furthermore, mitochondria are the site of the initial step of steroidogenesis: the
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cholesterol side-chain cleavage enzyme cytochrome P450 converting cholesterol to pregnenolone and
the 3β-hydroxysteroid dehydrogenase producing progesterone from pregnenolone are located in
mitochondria [48]. Treatment with 17β-estradiol or progesterone of ovariectomized rats enhanced the
brain mitochondrial respiration, whereas the coadministration of both did not [49].
5. The DCA Effect on the Mitochondrial ROS Generation and Gender
Under physiological conditions, a prime source of ROS is mitochondria: C I and C III are believed
to be the major sites for ROS production [50]. The ratio between electrons entering the respiratory chain
via FADH2 or NADH determines ROS formation; fatty acid oxidation increases the ratio, whereas it
appears to be low during glucose oxidation [51].
The PDK-targeted inhibition increases the production of mitochondrial ROS [5]. Sodium
dichloroacetate increases ROS generation in mitochondria [52,53]. Sodium dichloroacetate produces
the concentration- and time-dependent increase in the superoxide anion and nitric oxide production in
zebrafish mitochondria [54]. It is well known that ROS induce cell cycle arrest and apoptosis; DCA
affects cell growth and viability through the ROS production increase derived from the promotion
of oxidative metabolism [55,56]. The effects of DCA on multiple myeloma cell viability, cell cycle
arrest, and apoptotic cell death were associated with PDK inhibition, restored PDH activity, and the
promotion of oxidative metabolism in association with increased intracellular ROS production which
depends on the DCA dose [57]. The DCA effect cooperated with C I inhibition promoting the oxidative
stress in rat VM-M3 glioblastoma cells [7]. Increased ROS levels in DCA-treated cancer cells were
related to the induction of apoptosis associated with the increased cytochrome c expression [58].
Gender differences in hydrogen peroxide production in cardiocyte mitochondria in adult rats were
reported: female rats showed lower hydrogen peroxide production in cardiac mitochondria as compared
to males [33,59]. The depletion of female hormones by ovariectomy potentially enhanced oxidative
damage, whereas orchidectomy did not modify the oxidative stress parameters in mice [28]. The
treatment with androgens failed to reverse the orchidectomy-induced oxidative stress in rats, whereas
estrogen administration in ovariectomized females reversed it: these data imply the predominant role
of female hormones [28,60].
As compared with young male mice, young females have a higher mitochondrial glutathione
level, the major antioxidant in the brain [61]. Depletion of female steroids by ovariectomy enhances
the oxidative damage concomitantly with the decreased mitochondrial glutathione, but orchidectomy
did not modify these oxidative stress parameters in males [28].
Reduction in the activity of the respiratory complexes I–V with age in all rat organs together with
the age-dependent increase in oxidative stress and decline in NAD+ and ATP content was found; NAD+
is an essential electron transporter in mitochondrial respiration [62]. Males have a higher baseline
NAD+ level than female mice, and ovariectomized females showed a more “male-like” pattern of
the NAD+ level [63]. An increased NADH/NAD+ ratio favors the ROS generation [64]. The reduced
electron flow through the inhibition of C I or C III favors the enhanced production of superoxide and
H2O2, and mitochondrial generation of H2O2 due to the C I inhibition being more relevant than ROS
production due to the inhibition of complexes III and IV in situ [65–67]. The existence of progressive
disequilibrium between ROS generation and the antioxidant protective mechanisms during the aging
of both gender rats may be applicable to the human population [62,68].
6. The DCA Effect on Na–K–2Cl Cotransporter and Gender
The gender-related DCA effect on differences in the NKCC1 gene (Slc12a2) expression in rat
thymus was reported: the NKCC1 RNA expression levels in DCA-treated gonad-intact and castrated
males were significantly decreased, and no such effect was determined in the gonad-intact and castrated
female DCA-treated rats [8,69]. Sodium dichloroacetate treatment caused thymus weight decrease
in gonad-intact male and female rats, but no such treatment impact was determined in castrated
DCA-treated males and females [69]. This could indicate a synergistic effect of DCA with gonad
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hormones on thymocyte proliferation [70]. The NKCC1 is a known marker of cell proliferation and
apoptosis [71–73]; it is distributed in the cells of various tissues, among them, in the thymus [74,75].
Rat thymocyte NKCC1 functional activity is related to the intracellular chloride level which is sensitive
to the NKCC1 inhibitor furosemide [76–78]. The total NKCC1 protein levels of hypothalamus cells
were higher in the embryonic male than in female, and NKCC1 mRNA level was found to be higher in
males than in females on the day of birth [79].
The DCA effect on NKCC1 might be related to ROS, as the NKCC activity depends on the
oxidative stress [80,81]. Increased formation of ROS is related to the rat thymocyte proliferation
inhibition [82]. The DCA-treatment-related reduced thymus weight is linked with the DCA-induced
increase of thymocyte percentage in the G2–M cycle phase in male rat thymus [70]. The G2–M phase
arrest in multiple myeloma cell lines induced by DCA was reported, and the described effect was
supposed to be related to oxidative stress [57,83]. Sodium dichloroacetate causes ROS-dependent T-cell
differentiation [84].
Sodium dichloroacetate treatment caused a significant Hassall’s corpuscle (HC) number increase
in the thymus of gonad-intact male rats, and no such effect was found in the gonad-intact females.
However, no gender-related difference was found in the castrated rats of both genders [69]. Hassall’s
corpuscles represent an indirect differentiation feature of thymus epithelial cells [85,86] and thymocytes
apoptosis [87,88]. Thymocytes and thymic epithelial cells express androgen receptors [89].
It was reported that a single DCA dose caused a significantly higher 24 h diuresis in Wistar
male rats, and the increased diuresis was related to NKCC2 inhibition [8]. Gender differences
in renal NKCC2-related sodium handling have been noted in rats [90,91]. The NKCC2 is more
abundant in kidneys of intact females compared to intact males, with a greater transporter density
in Sprague–Dawley female rats; ovariectomy suppresses this gender difference and17-β estradiol
increases while progesterone decreases NKCC2 abundance in ovariectomized rats; these data
support the suggestion that the lower the NKCC2 expression in male rat kidney, the more they
are androgen-dependent [92]. The DCA effect on NKCC2 might be related to DCA-induced ROS
generation [80,81].
7. Preclinical Research of DCA Pharmacology
7.1. Pharmacokinetics and Bioavailability
Sodium dichloroacetate is rapidly absorbed from the gastrointestinal tract [93,94]; the absorption is
region-dependent: it is rapid in the stomach, duodenum, jejunum, and it is less in the ileum than in the
colorectal region [94]. After oral radio-labeled DCA administration to rats and mice, only about 1–2%
of the product was found in the feces [95,96]. Sodium dichloroacetate has a specific pharmacokinetics
characteristic: double peaks in DCA concentration–time profiles were observed after oral dosing in
rats [94,97,98]. The reason for the two absorption peaks was related to gastrointestinal-dependent
absorption; the second peak was absent when DCA was administered intravenously [94].
The DCA’s main distribution sites are the liver, muscles, skin, intestines, blood, and kidney; less
DCA was found in the lung, testis, spleen, heart, brain, bladder, and fat tissues [93,99], and after 48 h,
the tissues contained only 1–2% of the DCA dose [95].
Following transport across the cell membrane via the monocarboxylate transporter and across the
mitochondrial membrane via the pyruvate transporter, DCA enters the mitochondrial matrix [100].
Sodium dichloroacetate acts as a substrate and inhibitor of hepatic glutathione S-transferase-zeta1
(GSTζ) [101,102]. Sodium dichloroacetate inhibits its own metabolism: it can irreversibly inactivate
GSTζ making itself a mechanism-based self-inhibitor [103,104]. In rats and mice, high concentrations
of DCA were found to be incorporated into blood plasma proteins within 3 h of dosing [96].
Pharmacokinetic studies in rodents and dogs demonstrated the clear time-dependent non-linear
kinetics of DCA, with a high clearance decrease and high accumulation ratio after repeated
dosing [93,98,105]. The DCA distribution and plasma clearance in male animals following repeated
Cancers 2019, 11, 1210 6 of 28
dosing vary with species and age [93,94,96,100,105–107]. Following the intraperitoneal administration
of a single 38.5 mg/kg dose in male F344 rats, the hepatic level of GSTζ immunoreactive protein
decreased to less than 40% of the control value: subsequently, 7–8 days were required for the return of
the GSTζ protein level and DCA metabolism to control values [19]. Studies in rats have demonstrated
that changes in GSTζ activity are directly related to the elimination capacity and persistence of DCA.
Following the administration of 50 mg/kg DCA, the elimination half-life was age-dependent: it was
significantly shorter in male Sprague–Dawley rats aged 3–4 months than in those aged 16 months.
The maximum DCA plasma level following two doses was higher than after a single dose, and the
elimination half-life increased after the repeated dosing [93].
During the pharmacokinetics study, Fischer-344 male rats aged 8–10 weeks received 0.05–20 mg/kg
of DCA in naïve and GSTζ-depleted rats (GSTζ was depleted by exposing rats to 0.2 g/L DCA in
drinking water for 7 days). The GSTζ depletion significantly slowed the elimination of DCA. The
oral DCA bioavailability in naïve male rats dosed 5, 20 and 100 mg/kg was significantly lower than in
GSTζ-depleted ones (10%, 13%, 81% and 31%, 75%, 100%, respectively). The liver extraction of DCA in
the GSTζ-depleted rats had linear kinetics, but it decreased with the metabolism saturation at higher
doses [94]. Sodium dichloroacetate is unable to fully inhibit GSTζ activity in rats, and the existence of
a portion of DCA intrinsic hepatic clearance free from DCA self-inhibition was suggested [96,104].
The maximum (or peak) serum concentration values (Cmax) that a drug achieves in the body
after the drug has been administrated for DCA were greater in male rats relative to those in male
mice, while the half-life for DCA in the blood was similar in rats and mice [96]. The elimination of
i/v DCA doses in the young (10 weeks) and old (60 weeks) B6C3F1 male mice previously treated
with DCA in drinking water showed that DCA immediately reduces metabolism in young male
mice to a minimal level, which remains stable till the end of treatment. However, old male mice
undergoing chronic DCA treatment had the elimination rate comparable to that of controls, and both
young and old treated mice had similar DCA intrinsic metabolic clearances (0.84 and 0.76 mL/h/mg,
respectively) [107]. Following DCA treatment, the GSTζ activity in the liver cytosol was reduced
by over 80% in male mice aged 10 weeks but it was unaffected in old ones. A decrease in DCA
elimination in old mice is consistent with an age-related natural decrease in drug elimination [107].
Sodium dichloroacetate elimination is much slower in male dogs than in mice and rats, possibly
because of the striking inhibition of hepatic GSTζ, and dogs have the DCA kinetics similar to that in
humans [105,108]. Sodium dichloroacetate metabolism is extensive; only less than 3% of the dose is
excreted unchanged in young rats [95,96,109,110], whereas older rats given a dose excreted 7.4–37.2%
as the parent DCA [93,100,111].
The preclinical pharmacokinetic studies of DCA were conducted only in males [93,94,96,100,105–
107,109,112,113]; so, there is no possibility to compare gender-related differences; in some studies, there
are no data on the gender of the tested animals [114].
7.2. DCA Metabolism
Sodium dichloroacetate is eliminated mainly through GSTζ-catalyzed dechlorination to glyoxylic
acid, which is further metabolized by mitochondrial or cytosolic enzymes [97]. Sodium dichloroacetate
can also be dechlorinated to monochloroacetic acid in the blood [100,115]. The metabolism of DCA
in rodents decreases for prolonged administration [19,109,116,117] as DCA expresses a fast effect in
inhibiting its own metabolism after the first dosing, and an increased inhibition was noted after the
second oral dosing in male rats by inhibiting GSTζ [103]. In the pharmacokinetic model, measuring
plasma DCA concentrations in naive and male rats and mice pretreated with 2 g/L DCA in drinking
water, the estimated reduction in DCA metabolism among naive and 2 g/L pretreated rodents was
99% in rats and 76% in mice, showing significant species-related differences in DCA degradation [103].
The rate constants for DCA-dependent GSTζ inactivation in mouse, rat, and human liver cytosol were
different as rat > mouse > human [100,116].
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Radio-labelled [14C]DCA is metabolized to monochloroacetic acid, glyoxylic acid, glycolic acid,
oxalic acid, glycine, hippuric acid, carbon dioxide (CO2), and chloride anion [96,100]. Sodium
dichloroacetate is converted into CO2 through its major metabolite glyoxylic acid, and CO2 was a
major DCA metabolite. The CO2 excretion depends on the DCA dose or on its prior exposure in male
rats [93,96]. In male rats treated with a single DCA dose, exhaled 26% (fed) and 37% (overnight fasted)
as [14C]O2; in rats treated with two labelled DCA doses 24 h apart, 20% (fed) and 44% (overnight fasted)
DCA was recovered as CO2 [100,111]. Up to 30% of DCA was expired as CO2 in male mice [102]; in
others, mice exhaled only 2% of the dose as CO2 [96]. The glyoxylic acid, oxalic acid, and glycine
in male rat urine accounted for 9–44% of the administered dose, and their excretion depended on
the DCA dose and rat age [100]. The urinary excretion of unchanged DCA in male rats increases
with age, whereas oxalate and DCA end metabolites show the opposite trend [100]. It is notable that
preclinical studies of DCA metabolism are conducted only in male rats [93,95,96,100,109,117–121], male
mice [96,122] or male dogs [105], while some others do not indicate the gender of tested animals [99].
Glutathione (GSH)-dependent oxygenation of DCA to glyoxylic acid and its elimination proceed
mainly through GSTζ-catalyzed dechlorination in cytosol and mitochondria [102,110,123]. Of cytosolic
GSTζ, the AppKm for GSH obtained using female Sprague–Dawley rats is 2.5 fold higher than in males
and 3.2 fold higher than in male Fisher 344 rats; the higher AppKm for GSH with GSTζ indicates that it
has weakened access or binding to GSH [123]. Furthermore, the possible gender and gonad hormone
DCA metabolism dependency indirectly support data on gender-related differences of glycolate oxidase
participating in the metabolic conversion of glycolic acid to oxalate in the rat liver: the glycolate oxidase
activity was significantly lower in intact female and gonadectomized male rats as compared with
gonad-intact males; testosterone promotes and estrogen decreases glycolate oxidase activity in male
rats. Glycolate increased the urinary oxalate excretion dose-dependently in males but not in female
rats [124].
7.3. Side Effects of DCA
In animals, DCA has been shown to have side effects such as lowering the blood glucose
level [99,125–127] and the lactate level in blood serum and tumor tissue [126,128–130]. It has numerous
toxic adverse effects on the testicular tissue [131] and induced birth defects [54,97], while hepatomegaly
was consistently observed across species [97,132–134]. The high doses of DCA in male rats exhibited
peripheral hind leg neuropathy [133,135]. The DCA-related neuropathy is supposed to be caused by
the DCA metabolite oxalate [100,136], the generation of which from glycolic acid is gender- [123,124]
and age- [100] dependent, or it is related to tissue thiamine depletion [137]. Sodium dichloroacetate
treatment activates PDH with a concomitantly increase de novo CoA biosynthesis in ovarian cancer
cells, and induction of cytosolic CoA biosynthesis can aggravate DCA toxicity [138]. However, at
present, the relevance of DCA’s adverse effects in an animal to its gender-related human toxicological
profile has not been investigated.
7.4. DCA Hepatocancerogenic Effect
Sodium dichloroacetate is a genotoxic agent [139–142]. The Moore and Harrington-Brock review
concluded that the available genotoxicity data indicate DCA to be a weakly mutagenic agent causing
DNA point mutations and chromosomal aberrations [143]. Sodium dichloroacetate is classified as a
carcinogen [133,144].
Carcinogenicity studies in B6C3F1 male mice [135,145–153] and in F344 male rats [134,135] show
an increase in hepatic adenoma and adenocarcinoma cases after chronic treatment with DCA (Table 1).
Sodium dichloroacetate specifically stimulates the growth of hepatoadenomas rather than carcinomas,
but adenomas’ malignant transformations cannot be rejected. Sodium dichloroacetate induces liver
tumors in male rats at lower doses than in mice, and this strengthens the weight of data for DCA
tumorigenicity. Sodium dichloroacetate caused a significantly increased incidence of liver tumors
in male mice from different DCA dosages in drinking water [145,147–151,153,154]; the increase in
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tumor prevalence depends on the DCA concentration and exposure duration [151]. The B6C3F1
male mice studies have established that the ingestion of DCA results in an increased incidence of
hepatic adenocarcinomas at the dosages from 0.5 to 5 g/L in drinking water [145,147–151,153,154]: the
cancerogenic DCA doses in male mice were found at 1 g/L [150,151], at 2.0 g/L [151], at 3.5 g/L [147,150,
151,153,154] and at 5.0 g/L [145,149]; the dose of 0.5 g/L in drinking water, when the exposure was 104
weeks, in male mice induced adenocarcinomas in one study [148], while other researchers did not find
such a relationship [151,152].
There are only a few DCA carcinogenicity studies in female mice [146,155–157]. The histological
findings in female mice indicate the DCA hepatocarcinogenicity response in females to be related to
higher DCA doses and longer exposure duration as compared with males (Table 1). However, the
female mice carcinogenicity data were collected from studies investigating only females in different
laboratories [155–157], thus, the data cannot be adequately evaluated for gender-related differences. In
mature female mice, a significant increase in tumors was found only at the 3.5 g/L DCA dosage in
drinking water for 104 weeks [157], with the comparable tumor frequency in male mice treated with
the same dosage and duration [147,150,151].
The significant early-life DCA 3.5 g/L dose’s cancerogenic effect in unmatured (postnatal) mice
for 10 weeks treatment, followed by drinking water exposure until 98 weeks of age, was observed
both in male and female mice (histology was evaluated at 98 weeks): the tumor incidence comprised
85% and 86%, respectively [154]. It was predicted that short early-life postnatal DCA exposure may
alter the cancer risk later in life, resulting in a similar carcinogenic effect in mice livers of both genders
via epigenetic-mediated pathways affecting the oxidative cell metabolism [152]. Similar values were
reported in matured B6C3F1 male mice (Table 1) treated permanently with 3.5 g/L of DCA in drinking
water [150,151].
Miller et al. [158] showed DCA’s effect on liver tumor growth in mice, using magnetic resonance
imaging where DCA treatment in mice was prescribed until small tumors became apparent (1 mm in
diameter). The animals with tumors were randomly studied in groups: (1) in which treatment was
maintained and (2) in which treatment was suspended, where tumors were imaged over the next 2–3
weeks. The cessation of treatment abolished the growth of tumors [158]. Stauber et al. demonstrated
that the medium with DCA 0.5 mM increases the proliferation of c-Jun positive hepatocytes; c-Jun
is a nuclear transcription factor associated with cell transformation [159]. Studies demonstrate
the DCA-induced tumors are c-Jun positive [159,160]. In normal c-Jun negative hepatocytes, DCA
treatment consistently inhibits hepatocyte replication in vitro [155,161]. Furthermore, hepatocytes
from DCA-induced c-Jun-positive liver tumors are resistant to the DCA inhibitory effect on hepatocyte
proliferation [156]. Data from animals treated with DCA show that the dose–time-related hepatocyte
proliferation depression was accompanied by a suppression of spontaneous apoptosis [162].
The DCA-exposed mice study suggests that liver tumors can originate from eosinophilic, basophilic,
dysplastic, and clear cells [145,163]. The DCA-promoted tumor expresses the CYP2E1 and CYP4A1 of
cytochrome P450s [164]. Sodium dichloroacetate inhibiting GSTζ produces hepatocyte cytomegaly
due to the glycogen deposition related to the increased tyrosine metabolites level, and this supports
the hypothesis that the tyrosine metabolites may be cancerogenic agents [133,147,148,151]. We did not
find data which compare the gender-related difference of the DCA metabolism in relation to tyrosine
metabolites level. The DCA dose–response related to glycogen deposition in hepatocytes is similarly
required for inducing hepatocarcinogenesis [165]. Glycogen deposition could not be replicated by
exposing mice to the metabolites of DCA glycolate, glyoxylate, or oxalate in drinking water [166].
Furthermore, the GSTζ deficiency is related to an increased susceptibility to the oxidative stress and
activation of stress–response pathways [107,167,168]; oxidative stress is also closely associated with
tumor promotion mechanisms [169].
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Table 1. Preclinical studies of liver adenoma and carcinoma prevalence in male and female animals after exposure to different sodium dichloroacetate (DCA) doses in
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#: the number of experiments. Adenoma and carcinoma percentage frequency values shown in bold are significant compared with their control in the reference study.
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8. Experimental Research of DCA Monotherapy Efficacy in Cancer In Vivo
Experimental human cancer xenograft studies in vivo with the DCA treatment monotherapy
has been found to have antitumor properties in non-small cell lung cancer [83,170,171],
lung adenocarcinoma [172], breast adenocarcinoma [171,173], colorectal cancer [174,175],
neuroblastoma [176], glioblastoma [177], pancreatic cancer [178,179], hepatocellular carcinoma [53,180],
and ovarian adenocarcinoma [181]. Other researchers found that DCA treatment did not exert antitumor
activity against xenografted non-small cell lung cancer [170,182], breast adenocarcinoma [9,183], colon
and colorectal cancer [184–187], and glioblastoma [188,189] in vivo (Table 2). Furthermore, others
have reported colorectal cancer xenografted tumors to show a significant growth enhancement after
treatment with the DCA in vivo [184].
There are in vivo studies indicating no efficacy of DCA treatment on xenografted animal tumors:
the DCA treatment did not impact on the apoptosis of rat mammary adenocarcinoma cells [190]. The
DCA treatment promotes Neuro-2a cell tumor (murine neuroblastoma) growth in a female mouse
model bearing Neuro-2 tumors [191].
The limitations of several studies should be stressed, and in several cases, they could be evaluated
as some kind of inappropriate approach to investigation. As shown in Table 2, a remarkable number
of papers did not indicate the gender of animals used for research, and this concerns 46.7% of the
DCA-treated groups described in the manuscripts. It is understandable when the researchers used
female animals for breast or ovary cancer studies [9,173,183], but there was no grounded reason for
why they chose to conduct the studies on different genders in other cancer localizations. As shown in
Table 2, of all investigated animal groups, the sex was not indicated for 47% of cases. Experiments
with no DCA treatment efficacy according to the indicated sex of animals in 13 studied groups with
different localizations of cancer were as follows: 15.38% in males, 38.46% in females, and 46.15% where
the sex of animals was not indicated. An effective treatment was found in 16 groups: it comprised
25% in males, 31.25% in females, and 43.75% when the gender of the animals was not indicated
(Table 2); the described weaknesses do not allow for a comparison of the gender-related efficacy results.
Furthermore, different DCA dosages or their administration route were used. From the DCA efficacy
studies described in 29 papers, the age of animal groups used was not indicated in 33.3% of cases
(Table 2).
There are data reporting that the DCA parenteral administration was not effective in decreasing
tumor growth. This was the reason indicated for why researchers chose per os administration for the
DCA treatment [170]. As we can see from Table 2, I/P administration was used in nine study groups,
and the treatment efficacy was found in 44% of them; the per os administration was used in 21 tested
groups, and the treatment efficacy was determined in 57% of them.
The DCA oral dosage of 86 mg/kg/day in Fisher female rats aged 10–13 weeks is estimated to
result in DCA plasma concentrations up to 1.0 mM, while an additional 200 mg/kg/day I/P increases
plasma levels to 1.5–3.0 mM [94,110,192]. There was no change in the number of rat mammary
adenocarcinoma metastases in rats in the low-dose DCA group (with 0.5–1 mM of DCA in blood
serum), and the high-dose DCA group (1.5–3.0 mM of DCA) showed a significant reduction in lung
metastases [190]. Sodium dichloroacetate serum levels up to 1 mM were maintained in patients
chronically treated with an oral DCA administration of 25 mg/kg/day [193]. Sodium dichloroacetate
administration by oral gavage of 50 mg/kg twice daily is based on published reports: 100 mg/kg
mouse/day corresponds to approximately 13 mg/kg in humans [194], which is consistent with the
doses used in clinical settings [188]. Nude mice were administered 1.4 g/L DCA in drinking water
(corresponding to a calculated 100 mg/kg/day, used in patients) [195]. Studies have shown that the
daily consumption of 0.5 g/L DCA contained in drinking water resulted in increased PDH activity in
mouse tissue [196] and a serum level of DCA equivalent to that in DCA-treated humans [107,197].
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9. DCA as a Gender-Related Modulator in Cancerogenesis
Sodium dichloroacetate induces downstream pharmacological effects on tumor growth in vivo by
causing a shift in metabolism of cancer cells’ mitochondria, increasing mitochondrial function [171,
178,184,189,190,198] and ROS production [83,171], decreasing cell proliferation [171,173,190], and
enhancing apoptosis [83,171,198].
Through inactivation of PDH, PDKs divert the pyruvate away from mitochondrial respiration
and favor its conversion to lactate or alanine [199,200]. The PDK1 is a target of the hypoxia-inducible
factor (HIF-1), as the HIF-1-mediated expression of PDK1 increases lactic acidosis [201]. An association
between HIF-1 expression and gender are reported [202,203]. Females are more prone to lactic
acidosis frequency, and sex-linked mitochondrial genetic differences could increase susceptibility to
the development of lactic acidosis [204]. Sex hormones regulate the plasma lactate level: estrogen
upregulates but testosterone tend to downregulate lactate levels [205]. The accumulated lactate
could be used by tumor cells as an energetic fuel and appear as the factor responsible for tumor
resistance to treatment [192,206,207]. Sodium dichloroacetate suppresses lactate acidosis in the tumor
microenvironment [173,208,209]. Hypoxia is a feature of solid tumors associated with resistance to
therapy [210,211]. The hypoxic microenvironment stimulates epigenetic changes in gene expression
through the HIF-1 transcription factor in tumor cells [185,212]. Genes encoding HIF-1 were reproducibly
lower in DCA-treated cells when compared with respective controls [198].
Genetically, GSTζ-deficient mice show lymphocyte depletion not specific to DCA-treated
mice [213,214]. The DCA treatment was suggested to induce a stronger immune response to the
tumor as an increase in the number of T lymphocytes in tumor tissue [190], which may be related
to lactate level reduction in the tumor; a high lactic acid level has been shown to depress the
T cell function [207]. Several studies have reported DCA anti-tumor effects to be related to the
inhibition of angiogenesis, followed by the reduced tumor vascularity perfusion [171] and metastasis
suppression [190,208].
10. Experimental DCA Combination with Authorized Therapy
The DCA combination with other medicines in cancer therapy aims to achieve a synergistic
therapeutic effect, reducing drug dosage, drug toxicity, and minimizing or delaying the induction of
drug resistance. The DCA–arginase combination exhibited enhanced anti-cancer effects in preclinical
breast cancer models [9]. The bevacizumab and DCA combined treatment dramatically blocked
human glioma stem cell xenograft growth in female mice compared to either medicine alone, and
this indicates that combining DCA with antiangiogenic therapy represents a potential treatment
strategy [188]. Together with radiotherapy, DCA sensitized glioblastoma cells to radiotherapy, induced
cell cycle arrest at the G2–M phase, increased the oxidative stress in tumor cells, and improved the
survival of glioblastoma-bearing female mice [177]. The PDK2 overexpression and high glycolysis are
linked to cisplatin resistance in head and neck cancers; DCA significantly sensitized resistant head
and neck cancer cells with PDK2 overexpression to cisplatin in vitro and in xenograft tumor-bearing
male mice [215]. Sodium dichloroacetate helps to overcome the sorafenib resistance of hepatocellular
carcinoma in male mice [180]; it increased the capecitabine antitumor effects in a mouse B16 melanoma
allograft and in human lung cancer xenografts in male mice [182]. Sodium dichloroacetate, by inducing
in paclitaxel-resistant lung adenocarcinoma cells intracellular citrate accumulation, led to overcoming
the resistance by glycolysis inhibition and P-glycoprotein inactivation in male mice [172]. Sodium
dichloroacetate increased multiple myeloma cell line sensitivity to bortezomib, and the combined
treatment improved the survival of myeloma-bearing mice whose sex was not indicated in the
paper [57].
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11. Discussion
Defective oxidative phosphorylation has a relationship with mitochondrial function attenuation,
which is linked with resistance to cancer therapy. Mitochondria function restoration is a target
for cancer therapy [216]. Sodium dichloroacetate enhancing the mitochondrial function reverts the
hyperglycolytic nature of cancer cells, and, in this manner, tumor cells obtain an impaired proliferative
capacity and become more sensitive to apoptotic signals [217].
Sex-related mitochondrial function dimorphism is known in different organ cells of animals [28,33].
The information on different cell mitochondrial activity among genders at different ages in animals is
scant. The study of mitochondria-related genes in the heart myocytes in young, adult, and old male and
female Fischer 344 rats revealed differences among genders: adult males showed a higher expression
of genes associated with PDC compared to female rats; however, the majority of genes involved in
oxidative phosphorylation had a higher expression in old females than in age-matched males [33].
Clayton notes that female and male cells differ in their response to chemical agents. Therefore,
preclinical research should not ignore the effects of investigational medicines in relation to gender [218].
Gender differences in the expression of genes associated with the mitochondrial metabolism may
indicate the possible involvement of mitochondria in DCA-treatment susceptibility. As shown above,
data from DCA pharmacokinetics studies are available only on male animals, and, in the literature,
there are no comparative studies testing gender-related differences of DCA metabolism in animals.
Thus, DCA pharmacokinetics should be examined in animal species by evaluating gender-related
differences because the DCA pharmacokinetics of males cannot be directly scaled to females.
Sodium dichloroacetate efficacy may be dependent on multiple factors, including the ability to
metabolize DCA via GSTζ, or the overexpression of different PDK isoforms. The four PDK isoforms are
inhibited by different DCA concentrations [219] and they are expressed differently in organs [219,220].
Studies are necessary to determine the PDK isoform expression’s correlation with DCA sensitivity and
targeted tumors most sensitive to DCA in order to prognosticate which tumors and which gender are
most appropriate for DCA treatment. Sodium dichloroacetate has been shown to reverse resistance to
a number of agents when resistance to chemotherapy is mediated through the enhanced glycolytic
metabolism [180,188,215,221].
Sodium dichloroacetate treatment is evaluated as an adjuvant to chemotherapy [53,57,180,188,
221,222] to promote cancer cell death [215,223,224]. It has been suggested that DCA as a single agent
will be less effective and could be used in combination with the therapies that would benefit from an
enhanced oxidative metabolism [13].
One of the DCA treatment mechanisms is DCA-induced ROS production. Mitochondria are the
main cellular regulators of oxidative stress in relation to antioxidative mitochondrial systems [37]
which are also related to gender [29,62]. Thus, it is possible to hypothesize that ROS generation under
DCA exposure could be age- and gender-dependent in animals.
The elucidation of DCA impact on cancer cell NKCC1’s functional activity in relation to gender and
gonad hormones requires further studies. The induction of the NKCC1 RNA expression suppression
by DCA indicates that this effect may be related with the thymocyte intracellular chloride (Cl−)
concentration; the reduced intracellular Cl− level related to inhibitedNKCC1 could be an important
factor in cell proliferation and apoptosis. Researchers suggest that cytosolic Cl− could be one of the
key targets for anticancer therapy [71,225]. The NKCC1 plays an important role in the proliferation,
apoptosis, and invasion of cancer cells [71–73]; cancer with a high NKCC1 expression shows a potential
progression of tumor, and NKCC1 is recognized as a cancer therapeutic target [226]. A recent review
shows NaCl ions in a tumor microenvironment are involved in cancer progression [227]. Sodium
dichloroacetate inducing urine excretion of NaCl ions and causing changes in the extracellular and
intracellular Cl– concentration could have an important antitumorigenic effect [71,225,226].
The DCA gender-related different effect on thymus and on thymocyte NKCC1 could also be related
to the immune response. Thymus is a valuable model to investigate the effect of experimental medicines
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on elucidating the “non-visible immunological” effect of medicines in athymic animal models. Thus,
the DCA gender-related effect on thymocytes could elucidate a very important sphere, also.
Some researchers have reservations concerning DCA anticancer activity [2]; their disagreement
has focused on inequality in anticancer activity between in vitro and in vivo studies [228] and
effectiveness concerning the DCA dosage, including the administration route [170,190]. Environmental
conditions’ influence on cancer cells in vitro is very different from that of environmental states
in vivo. Misunderstanding in assessing DCA effectiveness may be due to the use of unreasonably
high DCA levels on investigating drug effects in vitro. For example, some papers present cancer
cells studied at very high sodium dichloroacetate levels (30, 50, 60, 80 or up to 120 mmol/L) in the
medium [58,175,229–231]. It is important to emphasize that such “therapeutic” dosages in vitro work
due to the hyperosmolar and hypernatraemic conditions in the media, and such sodium dichloroacetate
effects determine first of all the hyperosmolar conditions, and this could be evaluated not as medicine
efficacy, but as a misconduct of studies in vitro, as 150 mM and a higher level of sodium in blood serum
mean a hypernatremic condition, and the blood serum sodium of 170 mM is a mortal condition for a
human [232].
12. Conclusions
Research on investigational medicines needs to increase awareness of gender-related differences
in preclinical and clinical trial phases of pharmaceuticals development as recommended by scientific
and regulatory guidelines. Sodium dichloroacetate therapy and authorized therapy combinations with
DCA might offer additional treatment options and be a potential new therapeutic regimen against
some cancers, which could help overcome resistance to chemotherapy. Further evaluation of DCA and
radiotherapy as well as DCA and authorized chemotherapy combinations as treatment approaches to
personalized medicine in relation to gender remain important.
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